Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q96SF7

UPID:
TBX15_HUMAN

ALTERNATIVE NAMES:
T-box transcription factor TBX14

ALTERNATIVE UPACC:
Q96SF7; Q08E76; Q5JT54; Q5T9S7

BACKGROUND:
The T-box transcription factor TBX15, also referred to as TBX14, is a probable transcriptional regulator critical for the development of various skeletal structures, including the limb skeleton, vertebral column, and cranial bones. It achieves this by modulating the proliferation and differentiation of precursor cells into chondrocytes.

THERAPEUTIC SIGNIFICANCE:
Linked to the rare genetic disorder Cousin syndrome, TBX15's gene mutations result in distinctive skeletal malformations and developmental challenges. Exploring the functions of T-box transcription factor TBX15 offers a promising pathway to novel treatments for skeletal dysplasia disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.